Quercetin and dasatinib associated with epigenetic aging measures over 16 weeks in healthy individuals
This observational study examined whether the senolytics quercetin and dasatinib affected epigenetic aging rates in healthy individuals over 16 weeks. Participants underwent epigenetic age testing at baseline, the 8-week midpoint, and after 16 weeks. The abstract does not report what effects were actually found.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 3, 2021 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Observational
- Sample size
- —
- Duration
- 4 months
- Population
- Healthy individuals
- Primary outcome
- Epigenetic biological aging rates
- Effect size
- —
- Significance
- Not reported
- Journal
- TruDiagnostic
- Published
- Aug 3, 2021
Sources
Primary source
- TruDiagnostic ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.